Marc Fellous
Direttore Tecnico/Scientifico/R&S presso PMV PHARMACEUTICALS, INC.
Provenienza dei contatti di primo grado di Marc Fellous
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Public Company | Miscellaneous Commercial Services | 17 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Marc Fellous tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Sales & Marketing Comptroller/Controller/Auditor Corporate Officer/Principal | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
CELGENE | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
IMMUNOMEDICS, INC. | Biotechnology | Director/Board Member | |
PFIZER, INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
ARRAY TECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ARCH Venture Partners LLC
ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin. | Investment Managers | Private Equity Analyst | |
ATYR PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Consultant / Advisor | |
TRACON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
PELOTON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
The Trustees of Columbia University in The City of New York | College/University | Graduate Degree | |
Nextech Invest AG
Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Investment Managers | Private Equity Investor | |
MIRATI THERAPEUTICS | Biotechnology | Director/Board Member Chief Executive Officer Director of Finance/CFO | |
Fordham University
Fordham University Other Consumer ServicesConsumer Services Fordham University provides college and university. It offers undergraduate colleges and graduate & professional schools. The company was founded in 1841 and is headquartered in Bronx, NY. | College/University | Masters Business Admin Masters Business Admin | |
The University of Texas at Austin | College/University | Undergraduate Degree | |
Technische Universität Darmstadt | College/University | Undergraduate Degree | |
University of Zurich | College/University | Doctorate Degree | |
Amgen Ltd.
Amgen Ltd. Miscellaneous Commercial ServicesCommercial Services Amgen Ltd. operates as a biotechnology firm. It engages in the research and development of human therapeutics to treat illnesses. The company was founded on March 1, 1989 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | Pharmaceuticals: Major | Director/Board Member | |
Ecole Supérieure de Technologie des Biomolécules de Bordeaux | College/University | Graduate Degree | |
BLUEPRINT MEDICINES CORPORATION | Biotechnology | Director/Board Member | |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
ImaginAb, Inc.
ImaginAb, Inc. Medical SpecialtiesHealth Technology ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA. | Medical Specialties | Director/Board Member | |
Seragon Pharmaceuticals, Inc.
Seragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Seragon Pharmaceuticals, Inc. developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer. The company was founded in 2013 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Founder | |
Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Circle Pharma, Inc.
Circle Pharma, Inc. BiotechnologyHealth Technology Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Director/Board Member | |
POSEIDA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
IDEAYA BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
BLACK DIAMOND THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Mavupharma, Inc.
Mavupharma, Inc. Pharmaceuticals: MajorHealth Technology Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA. | Pharmaceuticals: Major | Director/Board Member | |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Biotechnology | Chairman | |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Packaged Software | Chairman | |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
MOMA Therapeutics, Inc.
MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
ACRIVON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | Packaged Software | Director/Board Member | |
RAYZEBIO, INC. | Biotechnology | Chairman | |
Moores Cancer Center | Corporate Officer/Principal | ||
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
ENLIVEN THERAPEUTICS, INC. | Biotechnology | Chairman | |
METACRINE, INC. | Biotechnology | Director/Board Member Founder | |
American Association For Cancer Research Foundation | Director/Board Member |
Statistiche
Distribuzione geografica
Stati Uniti | 46 |
Svizzera | 3 |
Germania | 2 |
Regno Unito | 2 |
Francia | 2 |
Settori
Health Technology | 36 |
Consumer Services | 8 |
Finance | 4 |
Technology Services | 3 |
Commercial Services | 2 |
Posizioni
Director/Board Member | 106 |
Corporate Officer/Principal | 45 |
Independent Dir/Board Member | 42 |
Undergraduate Degree | 16 |
Chairman | 13 |
Contatti più connessi
Insiders | |
---|---|
Carol Gallagher | 39 |
Richard Heyman | 33 |
Arnold Levine | 30 |
David Mack | 19 |
Thilo Schroeder | 18 |
Laurie Stelzer | 13 |
Charles Baum | 12 |
Winston Kung | 12 |
Timothy J. Smith | 8 |
Kirsten Flowers | 8 |
Robert Ticktin | 7 |
Deepika Jalota | 4 |
Michael Carulli | 4 |
Laura De Leon | 4 |
Crystal Zuckerman | 4 |
- Borsa valori
- Insiders
- Marc Fellous
- Connessioni Società